Anti‐TNF alpha medications and neuropathy

We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of the peripheral nervous system Ročník 20; číslo 4; s. 397 - 402
Hlavní autoři:	Tsouni, Pinelopi, Bill, Olivier, Truffert, André, Liaudat, Christelle, Ochsner, François, Steck, Andreas J., Kuntzer, Thierry
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Malden, USA Wiley Periodicals, Inc 01.12.2015 Wiley Subscription Services, Inc
Témata:	Adalimumab - adverse effects Adalimumab - therapeutic use Adult Aged anti‐TNF alpha Autoimmune Diseases - drug therapy demyelination Electrodiagnosis Etanercept - adverse effects Etanercept - therapeutic use Female Humans inflammation Infliximab - adverse effects Infliximab - therapeutic use Male Middle Aged Neural Conduction - physiology neuropathies Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - diagnosis Peripheral Nervous System Diseases - physiopathology Rheumatic Diseases - drug therapy Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF neuropathies anti-TNF alpha inflammation demyelination
ISSN:	1085-9489, 1529-8027, 1529-8027
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐TNF agents.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1085-9489 1529-8027 1529-8027
DOI:	10.1111/jns.12147